Skip to search formSkip to main contentSkip to account menu

sotagliflozin

Known as: Beta-l-Xylopyranoside, methyl 5-C-(4-chloro-3-((4-ethoxyphenyl)methyl)phenyl)-1-thio-, (5S)- 
An orally bioavailable inhibitor of the sodium-glucose co-transporter subtype 1 (SGLT1) and 2 (SGLT2), with potential antihyperglycemic activity… 
National Institutes of Health

Related topics

Related topics

1 relation

Narrower (1)

LX4211

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Review of Relative effectiveness assessments (REAs) of pharmaceuticals at the European network for health technology assessment(EUnetHTA): A first step towards a consolidated European perspective on…
Review
2019
Review
2019
In the Search of Glycoside-Based Molecules as Antidiabetic Agents
This review is an effort to summarize recent developments in synthesis of O-glycosides and N-, C-glycosyl molecules with… 
2019
2019
Dose‐dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial
To assess the dose‐related effects of sotagliflozin, a novel dual inhibitor of sodium‐glucose co‐transporters‐1 and ‐2, in type 1… 
Review
2019
Review
2019
Sotagliflozin: A Review in Type 1 Diabetes
Sotagliflozin (Zynquista™) is the first dual inhibitor of sodium-glucose co-transporter-1 and -2 (SGLT1 and 2). In the phase 3… 
Review
2019
Review
2019
Systematic literature review and network meta‐analysis of sodium‐glucose co‐transporter inhibitors vs metformin as add‐on to insulin in type 1 diabetes
To identify and synthesize phase 3 and phase 4 randomized controlled trials (RCTs) of sodium‐glucose co‐transporter (SGLT… 
Review
2018
Review
2018
Sotagliflozin: a combined SGLT1/SGLT2 inhibitor to treat diabetes
ABSTRACT Introduction: Sotagliflozin is the first dual SGLT1/SGLT2 inhibitor developed for use in diabetes. The agent blocks… 
Review
2016
Review
2016
THE EMERGING ROLE OF ADJUNCTIVE NONINSULIN ANTIHYPERGLYCEMIC THERAPY IN THE MANAGEMENT OF TYPE 1 DIABETES.
OBJECTIVE Review available data on adjunctive therapies for type 1 diabetes (T1D), with a special focus on newer… 
Review
2016
Review
2016
Intestinal SGLT 1 in metabolic health and disease
Lehmann A, Hornby PJ. Intestinal SGLT1 in metabolic health and disease. Am J Physiol Gastrointest Liver Physiol 310: G887–G898… 
Review
2015
Review
2015
Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor
The sodium-dependent glucose transporter 2 (SGLT2) inhibitors are an important emerging class for the treatment of diabetes… 
2015
2015
Sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes
Purpose Oral agents are needed that improve glycemic control without increasing hypoglycemic events in patients with type 1… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)